Dietmar Rohleder becomes CFO of Haupt Pharma AG
Rohleder takes over as Schwella focuses on production in Berlin
Rohleder takes over responsibility for the areas of finance, accounting and controlling from the previous CFO, Norbert Schwella. As a member of the extended Board committee, Schwella will retain responsibilities for purchasing and IT. In addition, he will be focussing on his role as md of the Group's Berlin production company. Under his leadership, this company has undergone a radical reorganisation over the past two years and today it is Haupt Pharma’s most important site for the production of solid drugs in the OTC segment.
Rohleder has 19 years of working in a wide range of roles in Deutsche Bank's loans and corporate banking business. In 2005 he was appointed to the Board of what is now INVITA AG, where he has been responsible for managing and controlling the holding company ever since.
By appointing Mr Rohleder as the CFO to its holding company Haupt Pharma AG, INVITA AG is demonstrating its support for the strategic path the company is following with the aim of becoming the leading contract manufacturer and developer in Europe.
You may also like
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Personal Protection
Gas safety in smaller pharmaceutical facilities
Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees